| dc.contributor | Consorci Sanitari de Terrassa |
| dc.contributor.author | Grau, Marta |
| dc.contributor.author | López, Cristina |
| dc.contributor.author | Navarro, Alba |
| dc.contributor.author | Frigola, Gerard |
| dc.contributor.author | Nadeu, Ferran |
| dc.contributor.author | Clot, Guillem |
| dc.contributor.author | Vicente Folch, Laura |
| dc.date.accessioned | 2023-08-25T12:09:16Z |
| dc.date.available | 2023-08-25T12:09:16Z |
| dc.date.issued | 2023-07-25 |
| dc.identifier.citation | Grau M, López C, Navarro A, Clot G, Frigola G, Nadeu F, et al. Unraveling the genetics of transformed splenic marginal zone lymphoma. Blood Adv. 2023 Jul 25;7(14):3695-3709. |
| dc.identifier.uri | https://hdl.handle.net/11351/10163 |
| dc.description | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Mutation |
| dc.description.abstract | The genetic mechanisms associated with splenic marginal zone lymphoma (SMZL) transformation are not well defined. We studied 41 patients with SMZL that eventually underwent large B-cell lymphoma transformation. Tumor material was obtained either only at diagnosis (9 patients), at diagnosis and transformation (18 patients), and only at transformation (14 patients). Samples were categorized in 2 groups: (1) at diagnosis (SMZL, n = 27 samples), and (2) at transformation (SMZL-T, n = 32 samples). Using copy number arrays and a next-generation sequencing custom panel, we identified that the main genomic alterations in SMZL-T involved TNFAIP3, KMT2D, TP53, ARID1A, KLF2, 1q gains, and losses of 9p21.3 (CDKN2A/B) and 7q31-q32. Compared with SMZL, SMZL-T had higher genomic complexity, and higher incidence of TNFAIP3 and TP53 alterations, 9p21.3 (CDKN2A/B) losses, and 6p gains. SMZL and SMZL-T clones arose by divergent evolution from a common altered precursor cell that acquired different genetic alterations in virtually all evaluable cases (92%, 12 of 13 cases). Using whole-genome sequencing of diagnostic and transformation samples in 1 patient, we observed that the SMZL-T sample carried more genomic aberrations than the diagnostic sample, identified a translocation t(14;19)(q32;q13) present in both samples, and detected a focal B2M deletion due to chromothripsis acquired at transformation. Survival analysis showed that KLF2 mutations, complex karyotype, and International Prognostic Index score at transformation were predictive of a shorter survival from transformation (P = .001; P = .042; and P = .007; respectively). In summary, SMZL-T are characterized by higher genomic complexity than SMZL, and characteristic genomic alterations that could represent key players in the transformation event. |
| dc.language.iso | eng |
| dc.publisher | American Society of Hematology |
| dc.relation.ispartofseries | Blood Advances;7(14) |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.source | Scientia |
| dc.subject | Leucèmia limfocítica crònica |
| dc.subject | Limfomes |
| dc.subject | Mutació (Biologia) |
| dc.subject.mesh | Leukemia, Lymphocytic, Chronic, B-Cell |
| dc.subject.mesh | Lymphoma, Large B-Cell, Diffuse |
| dc.subject.mesh | Mutation |
| dc.title | Unraveling the genetics of transformed splenic marginal zone lymphoma |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1182/bloodadvances.2022009415 |
| dc.subject.decs | leucemia linfocítica crónica de células B |
| dc.subject.decs | linfoma de células B grandes difuso |
| dc.subject.decs | mutación |
| dc.relation.publishversion | https://doi.org/10.1182/bloodadvances.2022009415 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.authoraffiliation | [Grau M] Molecular Pathology of Lymphoid Neoplasms, Fundació Clínic per a la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. [López C, Navarro A, Clot G] Molecular Pathology of Lymphoid Neoplasms, Fundació Clínic per a la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. Universitat de Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain. [Frigola G] Hematopathology Section, Department of Pathology, Hospital Clínic de Barcelona, Barcelona, Spain. [Nadeu F] Molecular Pathology of Lymphoid Neoplasms, Fundació Clínic per a la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain. [Vicente Folch L] Servei d’Hematologia, Hospital de Terrassa, Consorci Sanitari de Terrassa, Terrassa, Spain |
| dc.identifier.pmid | 36995085 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |